Department of Endocrinology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
J Neurooncol. 2013 Feb;111(3):313-8. doi: 10.1007/s11060-012-1015-0. Epub 2012 Dec 1.
Von Hippel-Lindau (VHL) is a tumor suppressor that negatively regulates the production of angiogenic factors. Mutations in the VHL gene cause VHL syndrome, which is characterized by highly vascularized tumors. Here we report a c.464T>A mutation of the VHL gene in three patients with hemangioblastoma from a Chinese family. This mutation was not reported previously and was absent in the unaffected family members. The mutation is predicted to cause Val to Glu substitution at VHL protein residue 155 in a conserved region. Previous biochemical studies demonstrated that residue Val-155 was critical for VHL protein binding to chaperonin TRiC/CCT, an essential step for proper VHL protein folding. Our finding of naturally occurring VHL V155E mutation in patients with VHL syndrome supports the functional importance of Val-155 residue in VHL protein and illustrates the diversity of VHL gene defects underlying VHL syndrome.
希佩尔-林道(VHL)是一种肿瘤抑制因子,可负向调节血管生成因子的产生。VHL 基因的突变导致 VHL 综合征,其特征是高度血管化的肿瘤。在这里,我们报道了一个来自中国家庭的三个血管母细胞瘤患者的 VHL 基因 c.464T>A 突变。该突变以前未报道过,在未受影响的家庭成员中也不存在。该突变预计会导致 VHL 蛋白残基 155 处的缬氨酸到谷氨酸取代,该残基位于保守区域。以前的生化研究表明,残基 Val-155 对于 VHL 蛋白与伴侣蛋白 TRiC/CCT 的结合至关重要,这是 VHL 蛋白正确折叠的必要步骤。我们在 VHL 综合征患者中发现自然发生的 VHL V155E 突变,支持 VHL 蛋白中 Val-155 残基的功能重要性,并说明了 VHL 综合征中 VHL 基因缺陷的多样性。